Original Research
Published on 16 Jan 2024
Circulating IL-6 and not its circulating signaling components sIL-6R and sgp130 demonstrate clinical significance in NSCLC patients treated with immune checkpoint inhibitors
in Cancer Cell Biology
- 2,833 views
- 1 citation